Regulation of cancer cell migration and bone metastasis by RANKL.
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Bone metastases are a frequent complication of many cancers that result in severe disease burden and pain. Since the late nineteenth century, it has been thought that the microenvironment of the local host tissue actively participates in the propensity of certain cancers to metastasize to specific organs, and that bone provides an especially fertile 'soil'. In the case of breast cancers, the local chemokine milieu is now emerging as an explanation for why these tumours preferentially metastasize to certain organs. However, as the inhibition of chemokine receptors in vivo only partially blocks metastatic behaviour, other factors must exist that regulate the preferential metastasis of breast cancer cells. Here we show that the cytokine RANKL (receptor activator of NF-kappaB ligand) triggers migration of human epithelial cancer cells and melanoma cells that express the receptor RANK. RANK is expressed on cancer cell lines and breast cancer cells in patients. In a mouse model of melanoma metastasis, in vivo neutralization of RANKL by osteoprotegerin results in complete protection from paralysis and a marked reduction in tumour burden in bones but not in other organs. Our data show that local differentiation factors such as RANKL have an important role in cell migration and the tissue-specific metastatic behaviour of cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDA-231 cells and other human breast cancer cells have been shown to express RANK (101, 336)”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [336]
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The distribution of secondary growths in cancer of the breast.
Paget, S. (1889) · The Lancet · doi:10.1016/s0140-6736(00)49915-0 · Cited by 5,277
Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Dissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351
Self-citationMetastasis to bone: causes, consequences and therapeutic opportunities
Mundy, G. R. (2002) · Nature Reviews Cancer · doi:10.1038/nrc867 · Cited by 2,777
The microenvironment of the tumour–host interface
Liotta, L. A., & Kohn, E. C. (2001) · Nature · doi:10.1038/35077241 · Cited by 2,310
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Fata, J. E., Kong, Y.-Y., Li, J., Sasaki, T., Irie-Sasaki, J., Moorehead, R. A., Elliott, R., Scully, S., Voura, E. B., Lacey, D. L., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00103-3 · Cited by 756
Self-citation
Cited by
Items 501–600 of 864
New Strategies for the Treatment of Metastatic Bone Disease
Pearse, R. N. (2007) · Clinical Breast Cancer · doi:10.3816/cbc.2007.s.010 · Cited by 13
Endocrine Therapy and Bone Loss in Breast Cancer: Time to Close in the RANK(L)?
Lønning, P. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0851 · Cited by 13
Mastrantoni, L., Garufi, G., Monte, E. D., Maliziola, N., Pasqualoni, M., Pontolillo, L., Pannunzio, S., Cannizzaro, M. C., Bello, A. D., Fabi, A., et al. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231173180 · Cited by 12
Methods to analyze cell migration data: fundamentals and practical guidelines
Wu, P.-H., Phillip, J. M., Du, W., Forjaz, A., Nair, P. R., & Wirtz, D. (2025) · Nature Methods · doi:10.1038/s41592-025-02935-5 · Cited by 12
Patkar, S., Magen, A., Sharan, R., & Hannenhalli, S. S. (2017) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1005793 · Cited by 12
“RANKL has been experimentally shown to induce cell migration in epithelial tumor cells expressing RANK, and is also an important osteoclast differentiation factor expressed in the bone marrow thereby creating a conducive environment for bone specific metastasis of RANK expressing tumor cells [36].”
Rajakumar, S. A., Grandal, I., Minden, M. D., Hitzler, J. K., Guidos, C. J., & Danska, J. S. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100470 · Cited by 12
“Engagement of the receptor activator of nuclear factor kB (RANK) with its ligand RANKL controls bone-specific metastatic behavior of breast cancer and melanoma cells.(16) We recently reported that RANK-RANKL interaction critically regulates B-ALL-mediated long bone destruction;(17) however, its role in CNS invasion is…”
BackgroundA Tailored Approach for Appendicular Impending and Pathologic Fractures in Solid Cancer Metastases
do Brito, J. S., Lopes-Brás, R., Abrunhosa-Branquinho, A. N., Fernandes, I., Gomes, I., Casimiro, S., & Costa, L. (2022) · Cancers · doi:10.3390/cancers14040893 · Cited by 12
“To add even more uncertainty, factors such as anatomic location and tumor biology, also influence the risk of pathologic fractures, although the extent and degree of that influence remain largely unknown [29,31,34,35,37,40,41].”
BackgroundA Novel Frailty Grade Combined with Cachexia Index and Osteopenia in Esophagectomy
Takahashi, K., Masuda, T., Ishikawa, Y., Tanishima, Y., Kurogochi, T., Yuda, M., Tanaka, Y., Matsumoto, A., Yano, F., & Eto, K. (2023) · World Journal of Surgery · doi:10.1007/s00268-023-06942-5 · Cited by 12
The many roles of RANKL-RANK signaling in bone, breast and cancer
Schramek, D., & Penninger, J. M. (2011) · IBMS BoneKEy · doi:10.1138/20110512 · Cited by 12
“Therefore, we initially speculated that this system might pay a role in hormone-driven breast cancer (16;58-60).”
BackgroundSelf-citationOsteoprotegerin (OPG) and Related Proteins (RANK, RANKL and TRAIL) in Thyroid Disease
Sood, S. K., Balasubramanian, S. P., Higham, S. E., Fernando, M. S., & Harrison, B. J. (2011) · World Journal of Surgery · doi:10.1007/s00268-011-1185-5 · Cited by 12
“melanoma cell lines [24].”
Osteoimmunology - Unleashing the concepts
Murthy, M. (2011) · Journal of Indian Society of Periodontology · doi:10.4103/0972-124x.85659 · Cited by 12
“[39,40] RANKL is of two types, a membrane associated cytokine and soluble cytokine.”
Denosumab: A Promising Drug for the Prevention and Treatment of Osteoporosis
Lewiecki, E. M. (2006) · Women s Health · doi:10.2217/17455057.2.4.517 · Cited by 12
“RANKL has been shown to trigger the migration of human epithelial cancer cells and melanoma cells, suggesting that inhibition of RANKL may offer protection against tumor metastasis and progression in bones [31].”
BackgroundPaul, D., & Nedelcu, A. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1040034 · Cited by 11
de Kort, W. W. B., Haakma, W. E., van Es, R. J. J., Gawlitta, D., Driehuis, E., Gansevoort, M., & Willems, S. M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186035 · Cited by 11
The RANK/RANKL axis controls vascular dynamics in the bone marrow
Kaneko, T., Yari, S., Kikuta, J., Omatsu, Y., Seno, S., Kikuchi, S., Sato, K., Fujii, K., Sudo, T., Hasegawa, T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425366122 · Cited by 11
“In addition to its originally identified roles in the skeletal and immune systems, lymph node organogenesis, and mammary gland development ( 38 , 39 ), pleiotropic functions of RANKL have recently been reported, including in cancer metastasis ( 40 , 41 ) and the central nervous system ( 42 , 43 ).”
Self-citationWimberger, P., Blohmer, J., Krabisch, P., Link, T., Just, M., Sinn, B. V., Simon, E., Solbach, C., Fehm, T. N., Denkert, C., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01619-2 · Cited by 11
“Although there is a great body of pre-clinical evidence that RANK signaling promotes proliferation and (bone) metastatic progression of breast cancer [23, 28, 29], it still controversially discussed, whether targeted inhibition of RANK signalling by denosumab treatment will confer clinical benefit in patients with ear…”
BackgroundRepurposing drugs for solid tumor treatment: focus on immune checkpoint inhibitors
Liu, Q., Li, L., Qin, W., & Chao, T. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0281 · Cited by 11
Park, R., Yu, J., Shahzad, M., Lee, S., & Ji, J. D. (2024) · Immunologic Research · doi:10.1007/s12026-024-09458-9 · Cited by 11
“The receptor activator of nuclear factor kappa beta ligand (RANKL) has been implicated in promoting cancer cell migration and bone metastasis [93].”
Kanzaki, H., Ohtaki, A., Merchant, F. K., Greene, M. I., & Murali, R. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.11.003 · Cited by 11
Image-guided Cryotherapy for Musculoskeletal Tumors
Scandiffio, R., Bozzi, E., Ezeldin, M., Capanna, R., Ceccoli, M., Colangeli, S., Donati, D. M., & Colangeli, M. (2020) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/1573405616666200825162712 · Cited by 11
Alonso, V., Pérez‐Martínez, F. C., Calahorra, F. J., & Esbrit, P. (2009) · Life Sciences · doi:10.1016/j.lfs.2009.07.005 · Cited by 11
Geldyyev, A., Koleganova, N., Piecha, G., Sueltmann, H., Finis, K., Ruschaupt, M., Poustka, A., Gross, M., & Berger, I. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.05.003 · Cited by 11
Plasminogen Activator System — Diagnostic, Prognostic and Therapeutic Implications in Breast Cancer
Leurer, C., & Rabbani, S. A. (2015) · InTech eBooks · doi:10.5772/59429 · Cited by 11
“It has also been shown that RANKL promotes the migration of RANK-expressing tumor cells to bone [28].”
BackgroundPicarda, G. G. A., Matous, E., Amiaud, J., Charrier, C., Lamoureux, F., Heymann, M., Tirode, F., Pitard, B., Trichet, V., Heymann, D., et al. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.04.004 · Cited by 11
“As an example, OPG was shown to inhibit cancer cell migration and bone metastasis through inhibition of the RANKL-induced effects in RANK-expressing cells from tumor origin [40].”
BackgroundFatty Acids and Calcium Regulation in Prostate Cancer
Maly, I. V., & Hofmann, W. A. (2018) · Nutrients · doi:10.3390/nu10060788 · Cited by 11
“In addition to being able to regulate the cell types of the bone microenvironment that express RANK, metastatic prostate cells themselves express this receptor and therefore also respond directly to RANKL with enhanced growth and invasive motility [199,200].”
BackgroundFrom bone to breast and back - the bone cytokine RANKL and breast cancer
Hofbauer, L. C., Rachner, T. D., & Hamann, C. (2011) · Breast Cancer Research · doi:10.1186/bcr2842 · Cited by 11
“Th ese fi ndings complement an earlier study from Josef Penninger’s group where RANKL enhanced breast cancer cell migration into bone and spurred the development of bone metastases [10].”
BackgroundRANK/RANKL Signaling Pathway in Breast Development and Cancer
Pérez-Chacón, G., Santamaría, P. G., Redondo-Pedraza, J., & González‐Suárez, E. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_16 · Cited by 10
A comprehensive review on pain: Model, target, therapy, and prospect (Review)
Chang, C., Wu, X., Liu, K., Wang, L., Adu, M., Lin, Q., Huang, H., Ma, Q., Wei, R., Wang, X., et al. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5717 · Cited by 10
“Denosumab, a monoclonal antibody targeting RANKL, suppresses osteoclast activation, reduces bone resorption, and increases bone density (209).”
Premnath, P., Tan, B., & Venkatakrishnan, K. (2015) · Scientific Reports · doi:10.1038/srep12141 · Cited by 10
Burch, S. A., & Lopez, C. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042003 · Cited by 10
“Abnormal cell migration plays a role in cancer metastasis [48] and is often the target of many therapeutic drugs [49,50].”
BackgroundKlauzińska, M., McCurdy, D., Rangel, M. C., Vaidyanath, A., de Castro, N. P., Shen, M. M., Gonzales, M., Bertolette, D. C., Bianco, C., Callahan, R., et al. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.07.023 · Cited by 10
“They are also involved in normal mammary gland development and tumorigenesis as a paracrine effector.(36,37) It has been reported that RANKL is responsible for the major proliferative response of the mouse mammary epithelium to progesterone,(37) which links the RANK/RANKL axis to progesterone.”
BackgroundVickman, R. E., Yang, J., Lanman, N. A., Cresswell, G. M., Zheng, F., Zhang, C., Doerge, R. W., Crist, S. A., Mesecar, A. D., Hu, C., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1054 · Cited by 10
“Elevated expression of RANKL has a known association with bone metastasis niche formation and cancer progression by promoting osteoclast-mediated bone resorption (27, 28).”
BackgroundMaru, Y. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a036897 · Cited by 10
“It was shown that the osteolytic lesions were also created by CD4+ T cells found in the bone cavity and draining lymph nodes in a manner in which tumor antigen-stimulated T cells express RANKL (Monteiro et al. 2013).”
BackgroundInfluentialImpact of denosumab on bone mass in cancer patients
Stopeck, A., & Brown-Glaberman, U. A. (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s30330 · Cited by 10
“74 76 Similarly, there is data supporting an integral role for RANK–RANKL in the spread and propagation of cancer cells in bone, helping to explain the osteotropism of tumors, including prostate, breast, and lung cancer, that express RANK.”
InfluentialOsteoblasts contribute to a protective niche that supports melanoma cell proliferation and survival
Ferguson, J., Wilcock, D. J., McEntegart, S., Badrock, A. P., Levesque, M. P., Dummer, R., Wellbrock, C., & Smith, M. P. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12812 · Cited by 10
“RANKL has also been shown to play a role in the ability of melanoma cells to home to, and grow within the bone niche (Jones et al., 2006).”
BackgroundBoyce, B. F., Zuscik, M. J., & Xing, L. (2012) · Elsevier eBooks · doi:10.1016/b978-0-12-387829-8.00001-9 · Cited by 10
Joint analysis of WES and RNA‐Seq identify signature genes related to metastasis in prostate cancer
Xiang, C., Li, Y., Wang, W., Tao, H., Liang, N., Wu, S., Yu, T., Cui, X., Xie, Y., Zuo, H., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17781 · Cited by 9
Hepatocellular carcinoma and musculoskeletal system: A narrative literature review
Jadzic, J. S., & Djonić, D. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i15.2109 · Cited by 9
“It has an activating effect on bone resorption through the OPG-RANKL pathway[44,72,73].”
DeBose-Scarlett, E. M., Ressler, A. K., Friday, C. M., Prickett, K. K., Roberts, J. W., Gossage, J. R., & Marchuk, D. A. (2025) · Journal of Medical Genetics · doi:10.1136/jmg-2024-110569 · Cited by 9
RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments
Gkikopoulou, E., Syrigos, C.-C., Mantogiannakou, I., Petraki, C.-E., Stathopoulou, M. S., Dragolia, M., Rinotas, V. E., Ntafis, V., Rauner, M., & Douni, E. K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26114990 · Cited by 9
“Unlike prior models that focus on RANKL inhibition in wild-type mice [5,24], our TgRANKL mouse model uniquely enables the direct testing of denosumab in mice.”
InfluentialAberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors
Szwarc, M. M., Kommagani, R., Jacob, A. P., Dougall, W. C., Ittmann, M., & Lydon, J. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128467 · Cited by 9
“Whether similar cellular changes are employed by the RANKL/RANK signaling axis during salivary gland tumorigenesis—as observed in tumor cells of the mammary gland [18, 21, 25, 42, 50, 52] as well as of the prostate gland [12, 20, 53], kidney [11], and liver [51]—is a research question to be addressed by future studies.”
BackgroundExploring new pathways in endocrine-resistant breast cancer
de Pinho, I. S., Abreu, C., Gomes, I., Casimiro, S., Pacheco, T. R., Sousa, R., & Costa, L. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00086 · Cited by 9
Jördens, M. S., Wittig, L., Loberg, C., Heinrichs, L., Keitel, V., Schulze-Hagen, M. F., Antoch, G., Knoefel, W. T., Fluegen, G., Loosen, S. H., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071660 · Cited by 9
Progestogens and risk of breast cancer: a link between bone and breast?
Ricarte, M. G., Pérez, A. D. C., Tarín, J. J., & Cano, A. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1078304 · Cited by 9
“The identification of RANK and RANKL in the breast came from a series of studies aiming at mapping these proteins in organs and systems [9].”
BackgroundInfluentialRANK/RANKL expression in prostate cancer
Ohtaka, M., Kawahara, T., Mochizuki, T., Takamoto, D., Hattori, Y., Teranishi, J.-I., Miyoshi, Y., Yumura, Y., Hasumi, H., Yokomizo, Y., et al. (2016) · International Journal of Surgery Case Reports · doi:10.1016/j.ijscr.2016.11.042 · Cited by 9
Peters, S., Danson, S. J., Ejedepang, D., Dafni, U. G., Hasan, B., Radcliffe, H.-S., Bustin, F., Créquit, J., Coate, L. E., Guillot, M., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.09.002 · Cited by 9
Logical structures extracted from metastasis experiments
Maru, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01300.x · Cited by 9
ZHANG, Y., Liu, X., Li, K., & BAI, J. (2014) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2014.2153 · Cited by 9
“Transgenic OPG mice (+/+) exhibited bone sclerosis, while OPG-knockout mice (OPG -/-) showed progressive aggravation of osteoporosis, with a reduction in the cortical and trabecular bone volume, thickness and number of cells (18).”
Treatment of osseous metastases using the Spinal Tumor Ablation with Radiofrequency (STAR) system
Ma, Y., Wallace, A. N., Madaelil, T. P., & Jennings, J. W. (2016) · Expert Review of Medical Devices · doi:10.1080/17434440.2016.1256772 · Cited by 9
Die Rolle des RANK/RANKL/OPG-Signalwegs im Knochenstoffwechsel
Hofbauer, L. C., & Rachner, T. D. (2010) · Springer eBooks · doi:10.1007/978-3-642-05385-6_26 · Cited by 9
Lebrét, T., Méjean, A., & Houédé, N. (2011) · The French Journal of Urology · doi:10.1016/j.purol.2010.12.001 · Cited by 9
The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases
Ferreira, A. R., Alho, I., Vendrell, I., Melo, M., Lopes-Brás, R., Costa, A. L., Sousa, A. R., Mansinho, A., Abreu, C., Pulido, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9356 · Cited by 9
“com/oncotarget RANK-RANKL pathway is a key regulator of bone physiology [1, 2], but also a central player in the onset of BM, as RANKL acts as a chemoattractant for RANKpositive tumor cells [20, 21].”
BackgroundBilen, M. A., Hess, K. R., Subudhi, S. K., Aparicio, A. M., Kim, J., Zurita‐Saavedra, A., Araujo, J. C., Corn, P. G., Stover, J. T., Lin, S.-H., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3391-9 · Cited by 8
“Regulatory T cells are a major source of RANKL, which mediates cancer cell mobility and bone metastasis [23, 24].”
BackgroundZhang, X., Song, Y., Song, N., Zhang, Y., Zhang, L., Wang, Y., Wang, Z.-N., Qu, X., & Liu, Y. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s110918 · Cited by 8
Galliera, E., Massaccesi, L., de Benedettis, E., Longhi, E., Toma, D. D., Romanelli, M. M. C., & Banfi, G. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ab0120-212rr · Cited by 8
Deligiorgi, M. V., & Trafalis, D. T. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1790522 · Cited by 8
Pathophysiology of Bone Metastases
Chirgwin, J. M., & Roodman, G. D. (2013) · Cancer metastasis · doi:10.1007/978-94-007-7569-5_1 · Cited by 8
Which Came First, Tumor Cells or Macrophages?
Maru, Y. (2007) · Cell Adhesion & Migration · doi:10.4161/cam.1.2.4489 · Cited by 8
Emerging candidates in breast cancer stem cell maintenance, therapy resistance and relapse
Singh, R., & Sharma, B. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.91119 · Cited by 8
“[54,55] Data from immunohistochemical studies on breast tumor tissues revealed that 90% of the normal breast tissue, 60% of the non-metastatic invasive ductal carcinoma (IDC), 31% of metastatic IDC, and 2% of osteolytic bone tumor metastases (BTM) lesions expresses RANK.”
Influentialde Sousa, B. L., Barroso-Neto, I. L., Oliveira, E. F., Fonseca, E. A., de Lima‐Neto, P., Ladeira, L. O., & Freire, V. N. (2016) · RSC Advances · doi:10.1039/c6ra16712h · Cited by 8
Pneumaticos, S. G., Christofides, A., Γκιόκα, Ε., Kalogeropoulos, T., Msaouel, P., & Koutsilieris, M. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.834889 · Cited by 8
“Targets (2013) 17(12) Moreover, the activation of the osteoclast-mediated bone resorption at the metastatic niche favors the release and/or activation of bone matrix-related growth factors, which are present in bone extracellular matrix (ECM), such as the latent transforming growth factor betas (TGFbs), bone morphogen…”
BackgroundMa, L., Wang, Y., Qiu, S., Shi, M., Tang, W., Hu, H., Li, C., Lu, H., & Wang, X. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02910-1 · Cited by 7
Management of metastatic bone disease of melanoma
Chen, W., Chen, Y., Chen, B., Xi, M., Chen, B., & Li, Q. (2023) · Melanoma Research · doi:10.1097/cmr.0000000000000937 · Cited by 7
MiR-143 Inhibits Osteoclastogenesis by Targeting RANK and NF-κB and MAPK Signaling Pathways
He, X., Zhu, L., An, L. K., & Zhang, J. (2020) · Current Molecular Pharmacology · doi:10.2174/1874467213666200116113945 · Cited by 7
Loss of MMP-27 Predicts Mandibular Bone Invasion in Oral Squamous Cell Carcinoma
Eichberger, J., Weber, F., Spanier, G., Gerken, M., Schreml, S., Schulz, D., Fiedler, M., Ludwig, N., Bauer, R. J., Reichert, T. E., et al. (2022) · Cancers · doi:10.3390/cancers14164044 · Cited by 7
“Additionally, RANKL is able to trigger cell migration in epithelial cancer cells [18].”
BackgroundSeaman, K., Lin, C., Song, X., Sassi, A., Du, W. W., Yang, B. B., Sun, Y., & You, L. (2025) · Advanced Biology · doi:10.1002/adbi.202400824 · Cited by 7
RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?
Resteghini, C., Alfieri, S., Quattrone, P., Dominoni, F., Garzone, G., Orlandi, E. M., Locati, L. D., Bergamini, C., Galbiati, D., Iacovelli, N. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21856 · Cited by 7
Association Between Preoperative Osteopenia and Prognosis in Breast Cancer Patients
Omori, S., Ijichi, H., Wakasugi, A., Shigechi, T., Oki, E., Kubo, M., & Yoshizumi, T. (2024) · Anticancer Research · doi:10.21873/anticanres.17074 · Cited by 7
“Interestingly, the RANK–RANKL system also induces epithelial–mesenchymal transition and stemness in human mammary epithelial cells and promotes mammary tumorigenesis, bone metastasis, and lung metastasis (23-25).”
BackgroundCross-Talk of Breast Cancer Cells with the Immune System
Demaria, S., Karsten, A., & Adams, S. (2011) · InTech eBooks · doi:10.5772/22545 · Cited by 7
“In addition to the expression of RANK on hematopoietic osteoclast precursors and DC, the receptor is also expressed by some tumor cell types, including melanoma, osteosarcomas, breast and prostate cancers (Jones et al., 2006; Mori et al., 2007a; Mori et al., 2007b).”
BackgroundDenosumab for treatment of breast cancer bone metastases and beyond
Nangia, J. R., JOSEPH, D. R., Nguyen, C. M., Mendes, M., & Trivedi, M. V. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.664634 · Cited by 7
“RANK is expressed in mature osteoclasts, dendritic cells and mammary glands as well as in breast and prostate cancer cells [34,44,45].”
BackgroundBispecific Antibody Binding To RANKL and Osteonectin with Enhanced Localization to the Bone
Chen, J.-H., Lin, C. Y., Chen, Y.-C. M., Tian, W., Chu, H., & Chang, T. W. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00501 · Cited by 7
Principles of management of extremity skeletal metastasis
Gulia, A., Gupta, S. M., Kurisunkal, V. J., Parikh, M., & Gupta, S. (2019) · Indian Journal of Palliative Care · doi:10.4103/ijpc.ijpc_90_19 · Cited by 7
Brook, N., Gill, J., Dharmarajan, A., Chan, A., & Dass, C. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232415641 · Cited by 7
“RANKL Promotes osteoclastogenesis; promotes osteolysis; Promotes BC cell homing to bone; [28,29]”
BackgroundTodenhöfer, T., Schwentner, C., Schilling, D., Gakis, G., & Stenzl, A. (2011) · Der Urologe · doi:10.1007/s00120-011-2623-6 · Cited by 7
Hirase, Y., Arigami, T., Matsushita, D., Shimonosono, M., Tsuruda, Y., Sasaki, K., Baba, K., Kawasaki, Y., & Ohtsuka, T. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04084-2 · Cited by 6
“Osteopenia is also reported to be induced by cancer-related inflammatory cytokines, which lead to osteoclast formation [21].”
Link, T., Blohmer, J., Schmitt, W., Kuhlmann, J. D., Just, M., Untch, M., Stötzer, O. J., Fasching, P. A., Thill, M., Reinisch, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-1801 · Cited by 6
Qi, Y., Wang, Y., Yuan, J., Xu, Y., & Pan, H. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02196-9 · Cited by 6
Nomogram Models Based on the Gene Expression in Prediction of Breast Cancer Bone Metastasis
Fan, T.-D., Bei, D., & Li, S.-W. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/8431946 · Cited by 6
Human receptor activator of NF-κB ligand (RANKL) induces osteoclastogenesis of primates in vitro
Kotake, S., Yago, T., Kawamoto, M., & Nanke, Y. (2012) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-012-9549-1 · Cited by 6
mAbs targeting RANKL in bone metastasis treatment
Gobin, B., Baud’huin, M., Isidor, B., Heymann, D., & Heymann, M. (2013) · doi:10.2217/ebo.12.295 · Cited by 6
Álvarez‐Carrión, L., Gutiérrez-Rojas, I., Rodríguez-Ramos, M. R., Ardura, J. A., & Alonso, V. (2021) · Cancers · doi:10.3390/cancers13030436 · Cited by 6
“Thus, prostate cancer cells ectopically express markers of bone, such as the bone formation transcription factor Runx2 or the bone resorption factor Receptor Activator of Nuclear Factor Kappa-β-Ligand (RANK-L) and behave as bone cells to adapt and grow in the bone microenvironment [6–9].”
BackgroundInfluentialPathophysiology of Bone Metastases
Roodman, G. D. (2009) · Cancer metastasis · doi:10.1007/978-1-4020-9819-2_2 · Cited by 6
Tang, Z.-N., Bi, X.-F., Chen, W., & Zhang, C.-L. (2023) · Clinical Breast Cancer · doi:10.1016/j.clbc.2023.01.014 · Cited by 6
Liu, Y. (2011) · Molecular Medicine Reports · doi:10.3892/mmr.2011.678 · Cited by 6
Morphologische Veränderungen des Knochengewebes bei Osteopetrose
Zustin, J., Amling, M., Crazzolara, R., Butscheidt, S., Schulz, A., & Oheim, R. (2017) · Der Pathologe · doi:10.1007/s00292-017-0370-1 · Cited by 6
Evolution of endocrine adjuvant therapy for early breast cancer
Lønning, P. E. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003714865 · Cited by 6
“Notably, bisphosphonates as well as the novel rank ligand (RANKL) inhibitors [75,76] are known to express toxic effects on tumour cells in vitro [77-79] apart from their osteoclast inhibiting functions, and the potential for both classes of compounds with respect to adjuvant therapy in pre- but also in postmenopausal…”
BackgroundOsteoclast biology and osteoimmunology
Nakashima, T. (2015) · Japanese Journal of Clinical Immunology · doi:10.2177/jsci.38.17 · Cited by 6
Self-citationYasuda, H. (2019) · Folia Pharmacologica Japonica · doi:10.1254/fpj.153.11 · Cited by 6
An, S., & Eo, W. K. (2024) · Medicine · doi:10.1097/md.0000000000038251 · Cited by 5
Liu, Y. C. G., & Teng, A. Y. (2024) · Immunity Inflammation and Disease · doi:10.1002/iid3.1173 · Cited by 5
Hirase, Y., Sasaki, K., Tsuruda, Y., Shimonosono, M., Uchikado, Y., Matsushita, D., Arigami, T., Tada, N., Baba, K., Kawasaki, Y., et al. (2024) · Esophagus · doi:10.1007/s10388-024-01101-8 · Cited by 5
“Similarly, osteopenia has been reported to potentially induce osteoclast formation through inflammatory cytokines [22].”
Inference of tumor phylogenies from genomic assays on heterogeneous samples
Subramanian, A., Shackney, S. E., & Schwartz, R. S. (2011) · ACM International Conference on Bioinformatics, Computational Biology, and Health Informatics (ACM-BCB) · doi:10.1145/2147805.2147824 · Cited by 5
“2 harbors the oncogene BCL2, which is involved in the MYC pathway [34] and TNFRSF11A, which is frequently expressed in late-stage breast cancers [35, 36].”
BackgroundCell lineage determinants as regulators of breast cancer metastasis
Lu, W., & Kang, Y. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9644-y · Cited by 5
Bouzid, A., Chelly, A., Tekari, A., Singh, N., Hansdah, K., Achour, I., Ayed, I. B., Jbeli, F., Charfeddine, I., Ramchander, P. V., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.870244 · Cited by 5
“The dysregulation of these balanced processes results in metabolic bone disorders, including osteoporosis, Paget’s disease, bone metastasis (22), and many other bone-related pathological conditions (23, 24).”
BackgroundRANK pathway in cancer: underlying resistance and therapeutic approaches
Tufail, M., & Wu, C. (2022) · Journal of Chemotherapy · doi:10.1080/1120009x.2022.2129752 · Cited by 5
“cells expressing RANKL to the bone matrix [51,52].”
BackgroundShimizu, S., Matsunaga, T., Sakano, Y., Makinoya, M., Shishido, Y., Miyatani, K., Kono, Y., Murakami, Y., Hanaki, T., Kihara, K., et al. (2023) · In Vivo · doi:10.21873/invivo.13375 · Cited by 5
“Osteopenia is reportedly associated with a poor prognosis because of tumor-derived cytokines ( e.g ., parathyroid hormone-related protein, interleukin-1, and interleukin-6), which stimulate osteoblasts and activate the NF-kB pathway (23).”
BackgroundIdentification of novel RANKL inhibitors through in silico analysis
Jiang, Y., Luo, X., Zheng, Z., Wen, S., Gao, H., Xu, C., Jiang, M., & Wang, S. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107826 · Cited by 5
The RANK Pathway in Advanced Breast Cancer: Does Src Play a Role?
Li, R., Zhang, K., Penedo, T. L., Kragel, C. P., Grizzle, W. E., Hameed, O. M., Siegal, G. P., & Wei, S. (2015) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000151 · Cited by 5
“for RANKL, resulted in a marked reduction in tumor burden in bones but not in other organs in a mouse model of melanoma metastasis.(8) With regard to breast cancer, RANKL stimulation is capable of inducing the migration of breast cancer cells.”
BackgroundSolid Tumours Show Osteotropism: Mechanisms of Bone Metastases
Roato, I., & Ferracini, R. (2013) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-013-9144-3 · Cited by 5
“RANK may induce migration and homing of tumour cells to the RANKL-rich bone microenvironment [22].”
BackgroundCasimiro, S., Alho, I., Bettencourt, M., Pires, R., Lipton, A., & Costa, L. (2013) · Journal of bone oncology · doi:10.1016/j.jbo.2013.07.001 · Cited by 5
“Bone metastases phenotype results from an unbalanced bone remodeling, where in a “vicious cycle” the tumor cells stimulate osteoclast activity, and have increased proliferation due to growth factors released from bone matrix upon bone resorption [3].”
Background
Metadata
- Authors
- Jones, D. H., Nakashima, T., Sanchez, O. H., Kozieradzki, I., Komarova, S. V., Sarosi, I., Morony, S., Rubin, E., Sarao, R., Hojilla, C. V., Komnenovic, V., Kong, Y.-Y., Schreiber, M., Dixon, S. J., Sims, S. M., Khokha, R., Wada, T., & Penninger, J. M.
- Affiliations
- Institute of Molecular Biotechnology (AT)
- University Health Network (CA)
- McGill University (CA)
- Amgen (United States) (US)
- University of Toronto (CA)
- Pohang University of Science and Technology (KR)
- Medical University of Vienna (AT)
- Western University (CA)
- Corresponding author
- Penninger, Josef M.
- ORCID
- Venue
- Nature
- Published
- 2006-03
- Volume
- 440
- Issue
- 7084
- Pages
- 692-696
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051255001
- Cited by
- 796
- References
- 22
- Citations by year
- 2026: 10 · 2025: 21 · 2024: 24 · 2023: 32 · 2022: 33 · 2021: 43 · 2020: 43 · 2019: 39 · 2018: 28 · 2017: 43 · 2016: 36 · 2015: 42 · 2014: 45 · 2013: 47 · 2012: 68
- FWCI
- 18.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- European Commission
- Oesterreichische Nationalbank
- Canadian Institutes of Health Research
- National Cancer Institute
- Institute of Musculoskeletal Health and Arthritis
- Canadian Arthritis Network
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Keywords
- RANKL, RANK, bone metastasis, tumor cell migration, osteoprotegerin, melanoma, breast cancer, tumor microenvironment, NF-κB signaling
- MeSH terms
- Animals, Bone Neoplasms, Breast Neoplasms, Carrier Proteins, Cell Differentiation, Cell Movement, Epithelial Cells, Female, Humans, Melanoma, Membrane Glycoproteins, Neoplasm Metastasis, Organ Specificity, Paralysis, Signal Transduction, Cell Death, Cell Line, Tumor, Cell Proliferation, Mice, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.